Jane Street Group LLC Purchases Shares of 26,570 MBX Biosciences, Inc. (NYSE:MBX)

Jane Street Group LLC acquired a new position in MBX Biosciences, Inc. (NYSE:MBX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 26,570 shares of the company’s stock, valued at approximately $690,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MBX. NEA Management Company LLC purchased a new position in MBX Biosciences during the 3rd quarter worth approximately $93,904,000. Wellington Management Group LLP acquired a new stake in shares of MBX Biosciences in the third quarter worth $74,261,000. RA Capital Management L.P. purchased a new position in shares of MBX Biosciences during the third quarter worth $39,264,000. Maven Securities LTD acquired a new position in MBX Biosciences during the third quarter valued at $1,299,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in MBX Biosciences in the third quarter valued at $1,200,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MBX shares. JPMorgan Chase & Co. initiated coverage on MBX Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $30.00 price objective for the company. Stifel Nicolaus initiated coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $40.00 price target for the company. Jefferies Financial Group began coverage on MBX Biosciences in a research report on Tuesday, October 8th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Guggenheim began coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $44.00 target price for the company.

MBX Biosciences Stock Up 1.9 %

MBX Biosciences stock opened at $18.59 on Friday. The stock’s 50-day moving average price is $20.30. MBX Biosciences, Inc. has a 12-month low of $15.31 and a 12-month high of $27.50.

MBX Biosciences (NYSE:MBX) last announced its earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). As a group, equities research analysts predict that MBX Biosciences, Inc. will post -13.21 earnings per share for the current year.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.